Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo.
Musi E, Schwartz GK, Yoo JH, Odelberg SJ, Li DY, Bonner MY, Selvakumar P, Rao S, Gilbert LC, Elsey J, Arbiser JL.
Musi E, et al. Among authors: gilbert lc.
Oncotarget. 2019 Jul 9;10(43):4424-4436. doi: 10.18632/oncotarget.27040. eCollection 2019 Jul 9.
Oncotarget. 2019.
PMID: 31320995
Free PMC article.